[
    [
        {
            "time": "2019-05-08",
            "original_text": "Novartis buys Takeda's dry eye drug for $3.4 bln",
            "features": {
                "keywords": [
                    "Novartis",
                    "buys",
                    "Takeda",
                    "dry eye",
                    "drug",
                    "$3.4 bln"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-08",
            "original_text": "Novartis buys dry-eye drug Xiidra rights from Takeda for $3.4 billion",
            "features": {
                "keywords": [
                    "Novartis",
                    "buys",
                    "dry-eye",
                    "drug",
                    "Xiidra",
                    "rights",
                    "Takeda",
                    "$3.4 billion"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-08",
            "original_text": "Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates",
            "features": {
                "keywords": [
                    "Aduro",
                    "Q1",
                    "Earnings",
                    "Revenues",
                    "Fall",
                    "Shy",
                    "Estimates"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-05-08",
            "original_text": "Novartis confident of Zolgensma supply, calls $2 million price 'speculation'",
            "features": {
                "keywords": [
                    "Novartis",
                    "confident",
                    "Zolgensma",
                    "supply",
                    "$2 million",
                    "price",
                    "speculation"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novartis confident of Zolgensma supply, calls $2 million price 'speculation'",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-08",
            "original_text": "Validea Peter Lynch Strategy Daily Upgrade Report - 5/8/2019",
            "features": {
                "keywords": [
                    "Validea",
                    "Peter Lynch",
                    "Strategy",
                    "Daily",
                    "Upgrade",
                    "Report"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]